Identify Patients

In asymptomatic or minimally symptomatic mCRPC patients, treat them early with PROVENGE Immunotherapy

6 month duration

Treat early

  • To stimulate your mCRPC patients’ immune systems while they have a lower tumor burden1

Treat confidently

  • The NCCN recommends PROVENGE as first-line treatment for asymptomatic or minimally symptomatic mCRPC2
  • Updated NCCN guidelines support the use of PROVENGE before enzalutamide, abiraterone, chemotherapy, and other treatments in asymptomatic or minimally symptomatic mCRPC patients who have progressed2
  • PROVENGE does not preclude the use of subsequent therapies3,4

*Radiographic evidence of disease progression or rising prostate-specific antigen (PSA).
ADT=androgen deprivation therapy; mCRPC=metastatic castrate resistant prostate cancer; NCCN=National Comprehensive Cancer Network.

Most CRPC patients fit in the PROVENGE window at the time of metastatic diagnosis

6 month duration

Treat early — make sure your patients take advantage of the PROVENGE window

Keep in mind that if your patient:

Candidate for Provenge

He is a candidate for PROVENGE3

*Radiographic evidence of disease progression or rising PSA.

Learn about Mike's Experience with PROVENGE


  1. Data on file. Dendreon Corporation.
  2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V1.2015. Accessed December 10, 2014.
  3. Provenge [prescribing information]. Seattle, WA: Dendreon Corporation; 2014.
  4. Cheever MA, Higano CS. PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520-3526.
  5. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(S2):S72-S79.
  6. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.